Reimbursement for several wound care products cut
Rehab Regs, April 6, 2007
Following a late 2006 U.S. Food and Drug Administration ruling, CMS will no longer pay for several wound care products, including Xenaderm Ointment, reported Medicare & Reimbursement Advisor Weekly. Therapists use Xenaderm as a topical treatment to promote the healing of decubitus/pressure ulcers.
Therapists said that despite the product's high cost, it saved time in the healing process and had positive clinical outcomes, which saved money over time. Additional wound care products no longer receiving Medicare reimbursement include BCT-Allenderm-T, trypsin complex, Optase Gel, Granulex, and Granulderm & TBC, reported Medicare & Reimbursement Advisor Weekly.
Most Popular
- Articles
-
- HIPAA Q&A: Answering service messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Volume requirement for reporting hydration services
- Q&A: Coding for dry skin due to cold weather
- Are your workforce members texting PHI?
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- OB services: Coding inside and outside of the package
- Catch up on what's new with injections and infusions
- Privacy, security concerns high in HIEs
- E-mailed
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Volume requirement for reporting hydration services
- HIPAA Q&A: Level of encryption needed for email
- HIPAA Q&A: Answering service messages
- Q&A: Coding for sepsis when other conditions are present
- HIPAA Q&A: TPO disclosures to a business associate
- Are your workforce members texting PHI?
- Q&A: Coding for dry skin due to cold weather
- What does case-mix index mean to you?
- Don't let these sentinel events trigger falsely
- Searched